These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 28748576)

  • 1. Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia.
    Homma Y; Gotoh M; Kawauchi A; Kojima Y; Masumori N; Nagai A; Saitoh T; Sakai H; Takahashi S; Ukimura O; Yamanishi T; Yokoyama O; Yoshida M; Maeda K
    Int J Urol; 2017 Oct; 24(10):716-729. PubMed ID: 28748576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].
    Descazeaud A; Robert G; Delongchamps NB; Cornu JN; Saussine C; Haillot O; Devonec M; Fourmarier M; Ballereau C; Lukacs B; Dumonceau O; Azzouzi AR; Faix A; Desgrandchamps F; de la Taille A;
    Prog Urol; 2012 Dec; 22(16):977-88. PubMed ID: 23178093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Withdrawing α1-Blocker from Combination Therapy with α1-Blocker and 5α-Reductase Inhibitor in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: A Prospective and Comparative Trial Using Urodynamics.
    Matsukawa Y; Takai S; Funahashi Y; Majima T; Kato M; Yamamoto T; Gotoh M
    J Urol; 2017 Oct; 198(4):905-912. PubMed ID: 28499730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.
    Gratzke C; Bachmann A; Descazeaud A; Drake MJ; Madersbacher S; Mamoulakis C; Oelke M; Tikkinen KAO; Gravas S
    Eur Urol; 2015 Jun; 67(6):1099-1109. PubMed ID: 25613154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of intravesical prostatic protrusion and resistive index is useful to predict bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
    Suzuki T; Otsuka A; Ozono S
    Int J Urol; 2016 Nov; 23(11):929-933. PubMed ID: 27545297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravesical prostatic protrusion can predict therapeutic response to silodosin in male patients with lower urinary tract symptoms.
    Matsukawa Y; Ishida S; Majima T; Funahashi Y; Sassa N; Kato M; Yoshino Y; Gotoh M
    Int J Urol; 2017 Jun; 24(6):454-459. PubMed ID: 28370376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-1 adrenergic antagonists, 5-alpha reductase inhibitors, phosphodiesterase type 5 inhibitors, and phytotherapic compounds in men with lower urinary tract symptoms suggestive of benign prostatic obstruction: A systematic review and meta-analysis of urodynamic studies.
    Fusco F; Creta M; De Nunzio C; Gacci M; Li Marzi V; Finazzi Agrò E
    Neurourol Urodyn; 2018 Aug; 37(6):1865-1874. PubMed ID: 29603785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outline of JUA clinical guidelines for benign prostatic hyperplasia.
    Homma Y; Gotoh M; Yokoyama O; Masumori N; Kawauchi A; Yamanishi T; Ishizuka O; Seki N; Kamoto T; Nagai A; Ozono S;
    Int J Urol; 2011 Nov; 18(11):741-56. PubMed ID: 22050351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
    Silva J; Silva CM; Cruz F
    Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
    Descazeaud A; Barry Delongchamps N; Cornu JN; Azzouzi AR; Buchon D; Benchikh A; Coloby P; Dumonceau O; Fourmarier M; Haillot O; Lebdai S; Mathieu R; Misrai V; Saussine C; de La Taille A; Robert G;
    Prog Urol; 2015 Jun; 25(7):404-12. PubMed ID: 25841758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.
    Oelke M; Bachmann A; Descazeaud A; Emberton M; Gravas S; Michel MC; N'dow J; Nordling J; de la Rosette JJ;
    Eur Urol; 2013 Jul; 64(1):118-40. PubMed ID: 23541338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.
    Dahm P; Brasure M; MacDonald R; Olson CM; Nelson VA; Fink HA; Rwabasonga B; Risk MC; Wilt TJ
    Eur Urol; 2017 Apr; 71(4):570-581. PubMed ID: 27717522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: the 1-year outcomes from a prospective urodynamic study.
    Matsukawa Y; Gotoh M; Kato M; Funahashi Y; Narita M; Mitsui K
    Int J Urol; 2014 Aug; 21(8):826-30. PubMed ID: 24661225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical therapy for benign prostatic hyperplasia: a review.
    Van Asseldonk B; Barkin J; Elterman DS
    Can J Urol; 2015 Oct; 22 Suppl 1():7-17. PubMed ID: 26497339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A urodynamic-based study.
    Matsukawa Y; Majima T; Matsuo K; Funahashi Y; Kato M; Yamamoto T; Gotoh M
    Int J Urol; 2018 Mar; 25(3):246-250. PubMed ID: 29164680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
    De Nunzio C; Presicce F; Tubaro A
    Drugs Today (Barc); 2016 Sep; 52(9):501-517. PubMed ID: 27883117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation and validation of the core lower urinary tract symptom score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: effects of the α1-adrenoreceptor antagonist silodosin.
    Ito H; Sano F; Ogawa T; Yao M
    Int J Urol; 2014 Jan; 21(1):108-12. PubMed ID: 23662900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Singapore Urological Association Clinical Guidelines for Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia.
    Singapore Urological Association Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Guidelines Committee 2015
    Singapore Med J; 2017 Aug; 58(8):473-480. PubMed ID: 28848988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
    Takahashi R; Miyazato M; Nishii H; Sumino Y; Takayama K; Onzuka M; Oshiro T; Saito S; Fujimoto N; Mimata H; Eto M
    Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early improvement of storage or voiding symptoms by tadalafil predicts treatment outcomes in patients with lower urinary tract symptoms from benign prostatic hyperplasia.
    Yokoyama O; Ozeki A; Suzuki N; Murakami M
    Int J Urol; 2018 Mar; 25(3):240-245. PubMed ID: 29094398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.